Abstract

United Therapeutics will release its quarterly results on May 6, 2026 Pre-Market, and this preview outlines consensus projections for revenue, profitability, and adjusted EPS alongside key product drivers, scenario analysis for the Tyvaso franchise, and a synthesis of prevailing institutional views.

Market Forecast

Consensus points to another period of top-line expansion for United Therapeutics in the upcoming report: revenue is estimated at 799.24 million US dollars, representing 9.51% year-over-year growth, while adjusted EPS is expected to be 6.88, up 5.32% year over year; EBIT is forecast at 351.01 million US dollars, implying a 6.48% year-over-year decline that likely reflects higher operating investments. Forecasts for gross margin and net margin have not been provided, though prior-quarter margins were elevated, and the company’s mix is not expected to materially shift away from its high-margin franchises this quarter. The company’s portfolio is expected to remain driven by the Tyvaso franchise, with ongoing uptake in pulmonary hypertension and continued physician adoption sustaining revenue momentum. The most promising segment remains Tyvaso: based on last quarter’s mix, it contributed an estimated 466.87 million US dollars and is positioned to carry the bulk of this quarter’s projected 9.51% year-over-year growth as prescription trends normalize after seasonal effects.

Last Quarter Review

United Therapeutics reported revenue of 790.20 million US dollars in the previous quarter, with a gross profit margin of 86.91%, GAAP net profit attributable to the parent company of 364.00 million US dollars, a net profit margin of 46.10%, and adjusted EPS of 7.70, up 24.39% year over year. Quarter on quarter, GAAP net profit increased by 7.56%, while adjusted EPS exceeded market expectations by 0.51, underscoring a robust margin profile despite modest operating deleverage at the EBIT line. In terms of business mix, the Tyvaso franchise accounted for an estimated 466.87 million US dollars of last quarter’s revenue based on mix proportions, with Remodulin at approximately 130.76 million US dollars and other treprostinil formulations at around 123.35 million US dollars, supporting total revenue growth of 7.38% year over year.

Current Quarter Outlook

Main business: The Tyvaso franchise’s revenue cadence and margin implications

The Tyvaso franchise is set to remain the center of gravity for this quarter’s revenue and profitability. Script trends exiting the last report period suggested healthy underlying demand, and management’s operational emphasis on product availability and patient support programs should continue to facilitate steady initiations and retention. With consensus modeling a 9.51% year-over-year revenue increase at the group level, Tyvaso’s scale and mix weight make it the principal driver of that growth cadence this quarter, even as other treprostinil-based modalities and legacy formulations contribute more modestly. From a margin standpoint, Tyvaso’s contribution is key to sustaining the company’s high gross margin profile. While gross margin guidance hasn’t been quantified for the quarter, prior-quarter gross margin of 86.91% provides a reference point for the unit economics of the inhaled treprostinil portfolio. Mix within the franchise can influence reported profitability: the balance between nebulized Tyvaso and Tyvaso DPI has implications for cost-to-serve and patient adherence patterns, yet both formats sit within a structurally high-margin respiratory specialty model. This mix nuance, combined with disciplined operating spend, explains the ability to deliver elevated net margins (46.10% last quarter) even as EBIT is projected to decline 6.48% year over year due to stepped-up investments and timing of expenses. Sequentially, adjusted EPS is forecast to moderate from 7.70 last quarter to 6.88 this quarter, which aligns with a typical pattern of operating expense timing early in the fiscal year and the investment ramp around late-stage programs. Importantly, the underlying revenue engine remains intact, and the quarter’s results will be read for signs that Tyvaso’s new and continuing patient trends are tracking toward the full-year build implied by consensus. The forward lens for the franchise includes addressing prescriber preferences across delivery modalities and ensuring capacity and logistics support are ahead of anticipated volume later in the year.

Most promising business: Tyvaso in idiopathic pulmonary fibrosis and portfolio catalysts

The near-term growth optionality centers on the Tyvaso program’s expansion, with newly reported pivotal results in idiopathic pulmonary fibrosis (IPF) for nebulized Tyvaso meeting the primary endpoint and improving multiple secondary measures. While IPF does not materially contribute to revenue in this to-be-reported quarter, it meaningfully shapes sentiment and the medium-term revenue narrative because it leverages the existing Tyvaso commercial infrastructure. The company has indicated plans to submit a supplemental new drug application by the end of summer 2026, framing potential label expansion timing and launch preparations. For the present quarter, investors will parse management’s commentary for the operational readiness milestones and any early market-development signals that ultimately translate into a broader patient reach upon approval. Alongside IPF, the late-stage advancement of ralinepag in pulmonary arterial hypertension—with pivotal data hitting the primary endpoint—adds another important catalyst path for the franchise. Management has set expectations for a new drug application submission in the second half of 2026, situating this quarter as a bridge period where the company must balance investment in launch readiness with disciplined cost control. The emergence of a soft-mist treprostinil inhaler program, designed to reduce cough and improve convenience while maintaining efficacy, provides an additional modality that could address specific patient preferences. This quarter’s update on development timelines and regulatory interactions for these programs will be closely correlated with how investors recalibrate multi-year revenue curves, even though near-term P&L impact remains dominated by the current Tyvaso line-up. Given these clinical and pipeline milestones, the most promising business in the eyes of the market remains the inhaled treprostinil franchise led by Tyvaso. Last quarter’s implied franchise revenue of approximately 466.87 million US dollars provides a scale baseline, and, for the current quarter, the same business is expected to underpin the group’s estimated 9.51% year-over-year growth. The strategic takeaway for this print is that the commercial execution of the existing indication, the clarity of regulatory timelines for IPF expansion, and continued late-stage development progress together shape both the qualitative tone of the quarter and the quantitative trajectory implied by consensus.

Factors that may drive the stock in this quarter’s print

The first determinant is the Tyvaso franchise’s realized growth rate relative to the 9.51% year-over-year revenue gain embedded in consensus. A top-line outcome that is either comfortably above or below this threshold will likely have an outsized influence on the stock’s immediate reaction, given Tyvaso’s centrality to group revenue and margin structure. Investors will focus on script trends, refill durability, new patient starts, and modality mix, as each of these sub-drivers helps explain any deviation from the baseline forecast. The second is operating leverage and expense timing, which together shape EBIT and EPS. Although EBIT is estimated to decline 6.48% year over year, the absolute level of profitability remains high, and even modest shifts in selling, general, and administrative expense or R&D phasing can move EPS relative to the 6.88 consensus. The last quarter delivered a 0.51 outperformance on adjusted EPS; the market will evaluate whether this quarter can similarly absorb investment timing and sustain earnings above model, especially if revenue arrives at or better than the 799.24 million US dollars estimate. The third is pipeline and regulatory visibility, which exerts influence on valuation multiples even when it has little immediate revenue effect. This encompasses the plan for a supplemental filing to expand Tyvaso’s label into IPF, the new drug application timeline for ralinepag, and progress updates on device and formulation innovation such as the soft-mist treprostinil inhaler. Separately, developments in organ assist and regenerative programs, including miroliverELAP receiving a regenerative medicine advanced therapy designation, add breadth to the company’s future optionality. In this quarter’s discussion, management’s specificity on submission timing, review interactions, and launch preparedness will be assessed for credibility and execution quality, which can tighten or widen the range of outcomes assumed by valuation models. A fourth factor is commercial guidance detail for the balance of the year. The market will look for commentary on payor dynamics, patient access, and supply chain preparedness across inhaled modalities. Any clarity around refill persistence, center-level adoption trends, or targeted support for specific subpopulations could lead to upward or downward adjustments to the revenue cadence for the second half of the year. This is especially relevant given the high base of revenue and the structurally high gross margins that make incremental revenue drops through to operating income at attractive rates. Finally, qualitative tone matters. Given the last quarter’s strong profitability and the elevated absolute margin levels, investors will pay attention to whether management frames the current quarter as an investment phase that still supports year-over-year EPS growth or whether the opex profile is signaled to stay higher for longer. Where commentary triangulates a steady revenue build with prudent cost growth, equity holders are more likely to look through quarter-to-quarter variability in EBIT to the medium-term inflection from label expansion and late-stage assets.

Analyst Opinions

Bullish views dominate recent institutional commentary on United Therapeutics in the past months, forming the clear majority of published ratings and target changes. UBS reiterated a Buy rating and highlighted the stock as a top pick on the strength of multiple near-term catalysts, notably the positive trajectory for Tyvaso and the de-risked outlook for IPF expansion timing; UBS also underscored the late-stage strength of ralinepag, emphasizing the potential for share capture upon launch and a broader franchise halo effect. Leerink Partners reaffirmed a Buy rating and pointed to sustained execution indicators in the core Tyvaso business, with attention to how trial readouts and regulatory timelines can re-rate the medium-term growth profile above baseline modeling. Jefferies maintained a Buy rating and lifted its price target to 575.00 US dollars, referencing the combination of commercial durability in the inhaled treprostinil franchise and strategic initiatives that diversify future revenue streams; the note tied ongoing clinical progress to a constructive stance on multi-year earnings power. TD Cowen echoed this thesis, reiterating a Buy with a 525.00 US dollars target, and framed recent clinical achievements as supportive of upward revisions to outer-year sales trajectories while acknowledging that the upcoming quarter is primarily about confirming the revenue cadence and capital allocation consistency required to support pipeline investment. In a related thread, RBC Capital raised its price target to 700.00 US dollars and maintained an Outperform rating, emphasizing that device and formulation innovation, including a soft-mist treprostinil inhaler, could strengthen patient adherence and expand addressable segments within the inhaled treprostinil family. Across these bullish opinions, a shared analytical core emerges: the current quarter is expected to validate that the Tyvaso engine can sustain near double-digit revenue expansion at the group level, and that operating discipline can deliver EPS growth even as EBIT normalizes alongside stepped-up R&D and launch readiness spending. Analysts consistently cite positive IPF and PAH late-stage results as underpinning a favorable medium-term setup. The majority view also anticipates that United Therapeutics will use this quarter’s call to sharpen timelines for regulatory filings—an approach that can improve visibility and reduce model variance on outer-year sales—while providing enough commercial detail to support confidence in 2026 revenue progression without needing to revise near-term cost assumptions higher. On valuation, the bullish camp argues that the combination of high gross margins, strong net margins, and a visible path to label expansion merits continued support for premium profitability metrics among specialty therapeutics peers. The dominant institutional stance expects management to strike a balance: reaffirming a trajectory that keeps revenue climbing toward the 799.24 million US dollars consensus mark this quarter and guiding credibly on expense pacing, thereby positioning adjusted EPS near or above the 6.88 estimate while leaving headroom for durable growth in subsequent quarters. In sum, the prevailing institutional narrative frames this report as an execution checkpoint on a longer runway of catalysts, with the Tyvaso franchise and late-stage assets providing the rationale for sustained positive sentiment.